Innate Pharma S.a.s.

Novo Nordisk A/s

Novo Norkisk A/s

Innate Pharma

Innate Pharma, S.a.

Joakim Glamann

Peter Andreas Nicolai Reumert Wagtmann

Francois Romagne

Francois RomagnÉ

François Romagnè

Peter Andreas Nicolaï Reumert Wagtmann

Compositions comprising anti-KIR antibodies and one or more secondary anti-cancer agents or anti-viral agents and methods of using such combinations (as combination compositions or in separate administration protocols) in the treatment of cancers (e.g., lung cancer) or viral infection (e.g., HIV or HCV infection) are provided.

Anti-KIR combination treatments and methods

Described are methods of treating viral disease using compounds that block inhibitory NK cell receptors, thereby reducing their inhibition of NK cell cytotoxicity in killing infected target cells. In one embodiment, the compound is an antibody binding, for example, one or more of the human KIR2DL1, KIR2DL2, and KIR2DL3 receptors. In another embodiment, the method further comprises administering a therapeutic antibody or fusion protein which binds an antigen expressed on cells infected with the virus.

Methods of enhancing antibody-based antiviral therapies by administering KIR2DL-binding antibodies

Methods of treating viral infections by administering KIR2DL-binding antibodies

Growing community of inventors

Gentofte, Denmark

Joakim Glamann